Good MorningEquity markets advanced on Tuesday, putting the S&P 500 at an all-time closing high. The move signals the market's willingness to continue the uptrend and may be a precursor to much higher price points. With earnings growth expected in 2025 and the potential for economic tailwinds to form by mid-year, the S&P 500 could sustain a rally through the end of 2025.
The stock rally is broadening. New highs in the Dow Jones Industrial Average, the Transportation Average, and the Russell 200 foreshadowed the move in the S&P. The move into other areas of the economy and small caps is a good sign but spells bad news for the previous market leaders. Names like NVIDIA, Amazon, Meta Platforms, and Microsoft may have difficulty setting new highs until sometime next year when sector rotation is completed. Featured: A letter from Shannon Stansberry (Ad) 
|
Healthcare | | Semler Scientific, Inc. (NASDAQ: SMLR) has been one of November’s hottest stocks, soaring over 130% as investors rally behind its newfound embrace of Bitcoin. The healthcare and medical devices company recently made waves by significantly expanding its Bitcoin holdings and introducing "Bitcoin... Read the Full Story |
|
From Our Partners | | The SpaceX IPO wasn't the big trade - according to Larry Benedict, founder of The Opportunistic Trader, it was the trigger. Benedict, who delivered a 279% return on cash in 2025 across a 20-year winning streak, says the listing launched what he calls the 'Final Phase of Elon's Master Plan.'
He's identified one specific ticker - not SpaceX, Tesla, or any Elon-affiliated company - that he believes could see billions in inflows as this phase unfolds. He calls it his trade of the year. | | Watch the video now to get the ticker name and full trade details |
|
Technology | |
Cerence (NASDAQ: CRNC) is an AI stock that has burst onto the radar of many investors lately. Since its latest earnings release on Nov. 21, shares have skyrocketed 155% as of the Nov. 25 close. So, what does this company do, and why am I mentioning it in the same breath as the lauded SoundHound AI... Read the Full Story |
|
Markets | |
When the biggest minds on Wall Street decide to make a significant move in their portfolios, retail investors better pay attention and attempt to reverse engineer the thinking and reasoning behind these moves. Today, investors can look at the recent 13-F filings from the Oracle of Omaha himself, W... Read the Full Story |
|
From Our Partners | | Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge.
Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks.
Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | | Watch Marc Chaikin's free presentation and get his full buy-and-sell list today |
|
Consumer Discretionary | |
Shares of Amazon.com, Inc. (NASDAQ: AMZN) have been having a standout year, with the stock building on the 150% rally that started in 2023. Though its shares have softened slightly in recent weeks, the tech titan was hitting fresh all-time highs just earlier this month. Even with this pullback, ... Read the Full Story |
|
Consumer Discretionary | | There are many reasons to own a stock, and the CEO is one of them. The right CEO can be the defining factor in a company’s success, shaping operations, driving growth, and delivering substantial shareholder returns. Strong leadership often signals not just steady performance but transformative... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Consumer Discretionary | |
Numerous stock buyback or repurchase authorization announcements were made throughout 2024. For the most part, they have become commonplace. A buyback authorization is not an obligation or requirement to buy back stock but more so permission to repurchase shares. The company has the option to buy ... Read the Full Story |
|
Technology | |
Pure Storage Inc. (NYSE: PSTG) is a leading enterprise data storage provider specializing in all-flash storage solutions using solid-state drives (SSDs). Their FlashArray is designed for low latency, scalable and reliable storage for applications requiring high-speed access to massive datasets l... Read the Full Story |
|
Markets | |
The spot price of gold has climbed by more than a third in the last year, repeatedly reaching all-time records in the last several months. Leading up to the November election—and amid a protracted period of investor uncertainty surrounding inflation and other concerns, as well as anticipatio... Read the Full Story |
|
Consumer Discretionary | |
As the United States gross domestic product (GDP) figures for the quarter recently suggested that the American consumer was mostly responsible for carrying economic growth, investors might wonder whether it is still worth it to look into buying some retail stocks in the cyclical space, or whether ... Read the Full Story |
|
Finance | |
After a few months of weakening data, home sales reports finally ticked higher, giving investors new hope for a rebound in the real estate sector. However, there is no reason to start celebrating yet, as other factors and themes need to fall back into line before the skies are clear for the indust... Read the Full Story |
|
Wednesday's Early Bird Stock Of The Day AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. | Should I Buy AbbVie Stock? ABBV Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of AbbVie was last updated on Saturday, August 29, 2026 at 6:04 PM.
AbbVie Bull Case -
AbbVie recently reported earnings per share of $3.65, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
-
The company has shown a year-over-year revenue increase of over 10%, suggesting robust demand for its products and effective business strategies.
-
AbbVie has a current stock price that reflects its strong market position, making it an attractive option for investors looking for stability in the biopharmaceutical sector.
-
The company announced a quarterly dividend of $1.73 per share, translating to an annualized dividend yield of 2.7%, providing a steady income stream for shareholders.
-
AbbVie has a diverse product portfolio and pipeline across major therapeutic areas, which positions it well for future growth and innovation in the healthcare market.
AbbVie Bear Case -
AbbVie has a negative return on equity of over 422%, which may raise concerns about the company's efficiency in generating profits from its equity base.
-
The dividend payout ratio is extremely high at 195.48%, indicating that the company is paying out more in dividends than it earns, which could be unsustainable in the long term.
-
Despite recent revenue growth, the company faces significant competition in the biopharmaceutical industry, which could impact its market share and profitability.
-
AbbVie is heavily reliant on a few key products for revenue, which poses a risk if any of these products face regulatory challenges or market saturation.
-
Market volatility and economic uncertainties could adversely affect AbbVie's stock performance, making it a riskier investment in the current climate.
| | View Today's Stock Pick |
|
